Heron Therapeutics, Inc.
HRTX
$0.34
$0.000.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.25% | -10.78% | -0.47% | 16.47% | 3.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.25% | -10.78% | -0.47% | 16.47% | 3.26% |
| Cost of Revenue | 11.59% | 21.30% | 10.88% | 10.49% | -14.44% |
| Gross Profit | -4.17% | -23.00% | -6.03% | 20.87% | 15.83% |
| SG&A Expenses | -2.34% | 5.76% | 10.70% | 15.32% | -5.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.25% | 10.43% | 10.77% | 13.52% | -8.55% |
| Operating Income | -24.86% | -251.08% | -99.09% | 8.19% | 74.60% |
| Income Before Tax | -130.53% | -407.82% | -180.64% | -260.87% | 74.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -130.53% | -407.82% | -180.64% | -260.87% | 74.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.53% | -407.82% | -180.64% | -260.87% | 74.22% |
| EBIT | -24.86% | -251.08% | -99.09% | 8.19% | 74.60% |
| EBITDA | -55.17% | -214.33% | -87.90% | 10.29% | 82.32% |
| EPS Basic | -85.81% | -348.84% | -165.69% | -223.97% | 74.42% |
| Normalized Basic EPS | -85.57% | -349.53% | -137.00% | -14.14% | 74.41% |
| EPS Diluted | -50.00% | -528.00% | -165.69% | -223.97% | 67.00% |
| Normalized Diluted EPS | -85.57% | -417.86% | -137.00% | -14.14% | 74.41% |
| Average Basic Shares Outstanding | 23.58% | 23.56% | 22.77% | 11.46% | 1.13% |
| Average Diluted Shares Outstanding | 23.58% | -3.69% | 22.77% | 11.46% | 1.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |